RG
NBIX icon

Renaissance Group’s Neurocrine Biosciences NBIX Stock Holding History

Renaissance Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.6M Sell
228,970
-17,407
-7% -$2.58M 1.57% 13
2026
Q1 		$32.5M Sell
246,377
-5,916
-2% -$785K 1.36% 25
2025
Q4 		$35.8M Buy
252,293
+665
+0.3% +$96.3K 1.44% 24
2025
Q3 		$35.3M Sell
251,628
-104
-0% -$14.1K 1.33% 28
2025
Q2 		$31.6M Buy
251,732
+39,632
+19% +$4.54M 1.23% 44
2025
Q1 		$23.5M Sell
212,100
-5,472
-3% -$693K 1.03% 53
2024
Q4 		$29.7M Buy
217,572
+13,432
+7% +$1.66M 1.23% 44
2024
Q3 		$23.5M Buy
+204,140
New +$28M 0.97% 54

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Group's NBIX Position: Q2 2026 in Review

Renaissance Group reduced its Neurocrine Biosciences (NBIX) stake by 7.1% in Q2 2026, selling an estimated $2.58M and leaving 228,970 shares worth $38.6M. The position accounts for 1.57% of the portfolio, ranked #13.

Renaissance Group first reported a position in NBIX in Q3 2024 and has held it in 8 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Renaissance Group held 228,970 shares of Neurocrine Biosciences worth $38.6M as of Q2 2026.
  • Renaissance Group sold 17,407 Neurocrine Biosciences shares in Q2 2026, an estimated $2.58M.
  • Neurocrine Biosciences made up 1.57% of Renaissance Group's portfolio in Q2 2026, its #13 holding.
  • Renaissance Group first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 8 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Renaissance Group's 13F filing for Q2 2026, filed 13 Aug 2026.